NEDA treatment target? No evident disease activity as an actionable outcome in practice

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

“No evident disease activity” (NEDA) is a proposed measure of disease activity-free status in multiple sclerosis (MS) that is typically defined as absence of relapses, disability progression, and MRI activity over a defined time period. NEDA is increasingly reported in randomized controlled trials of MS disease modifying therapies where it has some perceived advantages over outcomes such as annualized relapse rate. NEDA has also been proposed as a treatment goal in clinical care. At this point, the long-term implications of early NEDA remain largely unknown. We review current NEDA definitions, use in clinical trials, and its prospects for routine use as an actionable treatment target in clinical practice.

Original languageEnglish (US)
Pages (from-to)31-34
Number of pages4
JournalJournal of the Neurological Sciences
Volume383
DOIs
StatePublished - Dec 15 2017

Fingerprint

Multiple Sclerosis
Recurrence
Randomized Controlled Trials
Clinical Trials
Therapeutics

Keywords

  • Disease modifying therapy
  • Multiple sclerosis
  • No evident disease activity
  • Outcome measures
  • Treatment target

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

@article{b78f266cec8348a98eeddb944136ef4d,
title = "NEDA treatment target? No evident disease activity as an actionable outcome in practice",
abstract = "“No evident disease activity” (NEDA) is a proposed measure of disease activity-free status in multiple sclerosis (MS) that is typically defined as absence of relapses, disability progression, and MRI activity over a defined time period. NEDA is increasingly reported in randomized controlled trials of MS disease modifying therapies where it has some perceived advantages over outcomes such as annualized relapse rate. NEDA has also been proposed as a treatment goal in clinical care. At this point, the long-term implications of early NEDA remain largely unknown. We review current NEDA definitions, use in clinical trials, and its prospects for routine use as an actionable treatment target in clinical practice.",
keywords = "Disease modifying therapy, Multiple sclerosis, No evident disease activity, Outcome measures, Treatment target",
author = "Parks, {Natalie E.} and Eoin Flanagan and Lucchinetti, {Claudia F} and Wingerchuk, {Dean Marko}",
year = "2017",
month = "12",
day = "15",
doi = "10.1016/j.jns.2017.10.015",
language = "English (US)",
volume = "383",
pages = "31--34",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",

}

TY - JOUR

T1 - NEDA treatment target? No evident disease activity as an actionable outcome in practice

AU - Parks, Natalie E.

AU - Flanagan, Eoin

AU - Lucchinetti, Claudia F

AU - Wingerchuk, Dean Marko

PY - 2017/12/15

Y1 - 2017/12/15

N2 - “No evident disease activity” (NEDA) is a proposed measure of disease activity-free status in multiple sclerosis (MS) that is typically defined as absence of relapses, disability progression, and MRI activity over a defined time period. NEDA is increasingly reported in randomized controlled trials of MS disease modifying therapies where it has some perceived advantages over outcomes such as annualized relapse rate. NEDA has also been proposed as a treatment goal in clinical care. At this point, the long-term implications of early NEDA remain largely unknown. We review current NEDA definitions, use in clinical trials, and its prospects for routine use as an actionable treatment target in clinical practice.

AB - “No evident disease activity” (NEDA) is a proposed measure of disease activity-free status in multiple sclerosis (MS) that is typically defined as absence of relapses, disability progression, and MRI activity over a defined time period. NEDA is increasingly reported in randomized controlled trials of MS disease modifying therapies where it has some perceived advantages over outcomes such as annualized relapse rate. NEDA has also been proposed as a treatment goal in clinical care. At this point, the long-term implications of early NEDA remain largely unknown. We review current NEDA definitions, use in clinical trials, and its prospects for routine use as an actionable treatment target in clinical practice.

KW - Disease modifying therapy

KW - Multiple sclerosis

KW - No evident disease activity

KW - Outcome measures

KW - Treatment target

UR - http://www.scopus.com/inward/record.url?scp=85042648307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042648307&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2017.10.015

DO - 10.1016/j.jns.2017.10.015

M3 - Review article

C2 - 29246616

AN - SCOPUS:85042648307

VL - 383

SP - 31

EP - 34

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

ER -